ABHD17AP8

Across TCGA pan-cancer cohorts, ABHD17AP8 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated ABHD17AP8 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ABHD17AP8 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ABHD17AP8 expression acts as an unfavorable survival marker.

LIHC, KICH, and ESCA are the cancer types where ABHD17AP8 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	II,III,IV	0.337	0.722	<.001	72	view →
KICH	OS	Tertile	II,III,IV	0.070	0.828	<.001	54	view →
ESCA	OS	Tertile	II,III,IV	0.104	0.926	<.001	45	view →
LUSC	OS	Tertile	All	0.551	0.839	.001	39	view →
KIRP	DFS	Tertile	IV	0.088	0.502	<.001	36	view →
UCS	DFS	Tertile	IV	0.132	0.718	.002	36	view →
PAAD	OS	Tertile	All	0.138	0.590	<.001	27	view →
COAD	DFS	Tertile	All	0.460	0.789	.002	27	view →
PRAD	OS	Tertile	All	0.811	0.990	<.001	18	view →
UCEC	DFS	Tertile	All	0.244	0.660	.016	12	view →
STAD	DFS	Tertile	IV	0.083	0.379	.001	9	view →
THYM	DFS	Tertile	III,IV	0.214	1.000	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

ABHD17AP8–LIHC (OS)

Open the LIHC breakdown →